ConductScience.org, home

Gene · 10892

MALT1: MALT1 paracaspase

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. MALT1: MALT1 paracaspase. Genes, record 10892. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10892

On this page

Gene

Symbol
MALT1
HGNC
Name
MALT1 paracaspase
HGNC
NCBI Gene ID
10892
NCBI Gene
HGNC ID
HGNC:6819
HGNC
Ensembl
ENSG00000172175
NCBI Gene
Aliases
IMD12, MLT, MLT1, PCASP1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9UDY8Mucosa-associated lymphoid tissue lymphoma translocation protein 182426Ensembl, GeneID, HGNC

Source UniProt

Patents85

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026086608 A2026-05-261Q9UDY8Espacenet
JP 2026004568 A2026-01-1454162Q9UDY8Espacenet
EP 4661970 A12025-12-1762160Q9UDY8Espacenet
JP 2025172069 A2025-11-20535Q9UDY8Espacenet
EP 4650780 A22025-11-1919676Q9UDY8Espacenet
JP 2025524002 A2025-07-257Q9UDY8Espacenet
JP 2025517970 A2025-06-1219676Q9UDY8Espacenet
KR 1020250039465 A2025-03-207Q9UDY8Espacenet
US 12247982 B22025-03-11535Q9UDY8Espacenet
JP 2024028924 A2024-03-056Q9UDY8Espacenet

1 to 10 of 85

See all 85 patents

Drugs2

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
MEPAZINECHEMBL395110Mucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitorINHIBITORChEMBL
MEPAZINE ACETATECHEMBL1712842Mucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitorINHIBITORChEMBL

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,525

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleMALT1 papersNewest fiscal year
P30CA016672Cancer Center Support Grant152025
ZIABC011008Oncogenic mechanisms and molecular targets in lymphoma142025
P30CA008748Cancer Center Support Grant82025
P30CA047904Cancer Center Support Grant72025
ZIASC000550Lymphoma Disease Discovery and Definition72025
R01AI127564Genome-wide search for inborn errors of IL-17 immunity underlying chronic mucocutaneous candidiasis62025
ZIABC011070Hematopathology Diagnosis62025
P30CA046592University of Michigan Rogel Cancer Center Support Grant 2023-202852025
P30DK040561Boston Area Nutrition Obesity Research Center (NORC)52025
T32HL007622Boxer Training Program in Hematology52025

1 to 10 of 1,525Source NIH's project files

See all 1,525 nih grants

Papers2,863

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies.Blood Cancer Discov202642814116PubTator, text miningPubMed
Running on Empty Signals: What Human MALT1 Deficiency Reveals About Immune Control.J Immunol Res202642745540PubTator, text miningPubMed
Targeting intracellular immune regulatory molecules for cancer immunotherapy in solid tumors.Crit Rev Oncol Hematol202642732787PubTator, text miningPubMed
Effect of MALT1 inhibition by MI‑2 on the microglial phenotype switch, inflammatory cytokine secretion, neuronal loss and oxidative stress in Alzheimer's disease.Int J Mol Med202642695408PubTator, text miningPubMed
Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025.Exp Hematol Oncol202642665819PubTator, text miningPubMed
Epitranscriptomics, immunometabolism, and NETosis: unlocking novel mechanisms of traditional Chinese medicine in COPD.Front Immunol202642614789PubTator, text miningPubMed
A role for the protease MALT1 in EBV-mediated B-cell transformation by Latent Membrane Proteins 1 and 2.Leukemia202642595846PubTator, text miningPubMed
From Dynamics to Diagnosis and Therapy: A Multiscale Computational Framework for MALT1-Targeted Cancer Theranostics.J Chem Inf Model202642573397PubTator, text miningPubMed
[Clinicopathological features and prognosis of marginal zone lymphoma with aberrant CD10 expression].Zhonghua Bing Li Xue Za Zhi202642547419PubTator, text miningPubMed
The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma.iScience202642542590PubTator, text miningPubMed

1 to 10 of 2,863

See all 2,863 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/10892

GET https://conductscience.org/api/genes/v1/10892/patents?page=2